Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Contract Services
Return to: PBR Home | Contract Research & Services | Contract Services

Contract Services

Immune Pharma inks license and research deal with Yissum for AmiKet Nano Immune Pharmaceuticals (IMNP) has entered into a definitive license and research agreement with Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem, to license certain of Yissum's patents for the development and commercialization of a topical nano-formulated version of AmiKet, pursuant to the parties' existing binding memorandum of understanding from March 2015.
Contract Research & Services > Contract Services > News
Eolas, AstraZeneca to develop orexin-1 receptor antagonist to treat multiple indications By PBR Staff Writer
US-based Eolas Therapeutics and AstraZeneca have entered into a worldwide license and partnership agreement on the Eolas Orexin-1 Receptor Antagonist (EORA) program for smoking cessation and other indications.
Contract Research & Services > Contract Services > News Taisho to develop and commercialize Ablynx's rheumatoid arthritis drug ozoralizumab in Japan By PBR Staff Writer
Belgian biopharmaceutical firm Ablynx has entered a licence agreement with Japan-based Taisho Pharmaceutical to develop and commercialize its anti- TNFα nanobody, ozoralizumab, for the treatment of patients with rheumatoid arthritis (RA) in Japan.
Contract Research & Services > Contract Services > News
See more Contract Services news

Latest Contract Services News and Insight

View all Contract Services news or find news targeted to your interests
FibroGen receives $120m license payment from AstraZeneca
FibroGen (FGEN), a research-based biopharmaceutical company, announced that it has received a scheduled $120m non-contingent license payment from AstraZeneca under its collaboration agreements with AstraZeneca for roxadustat in the United States, China and certain other territories.
Contract Research & Services > Contract Services > News
Anacor makes changes to to Kerydin commercialization agreement
Anacor Pharmaceuticals (ANAC) announced an amendment to its distribution and commercialization agreement with Sandoz, a Novartis company, pursuant to which PharmaDerm, the branded dermatology division of Sandoz, distributes and commercializes KERYDIN (tavaborole) topical solution, 5%, in the United States.
Contract Research & Services > Contract Services > News
Pfizer to commercialize Tris' dextromethorphan cough syrup under Robitussin brand
By PBR Staff Writer
US-based Tris Pharma has entered into a license, supply, and distribution agreement with Pfizer Consumer Healthcare for the commercialization of its 12-hour extended release dextromethorphan cough syrup under the Robitussin Brand.
Contract Research & Services > Contract Services > News
Celgene, Juno to develop new immunotherapies for cancer and autoimmune diseases
By PBR Staff Writer
Celgene and Juno Therapeutics have entered into a ten-year collaboration to develop and commercialize new immunotherapies for patients with cancer and autoimmune diseases.
Contract Research & Services > Contract Services > News
Daiichi, Maruishi to commercialize Remifentanil Injection generic
By PBR Staff Writer
Japanese drugmaker Daiichi Sankyo and Maruishi Pharmaceutical have enter into a collaboration to commercialize the general anaesthesia analgesic, Remifentanil injection generic.
Contract Research & Services > Contract Services > News
Etubics, NCI partner to further develop therapeutic cancer vaccines
By PBR Staff Writer
US-based bio-pharmaceutical firm Etubics has entered into a cooperative research and development agreement (CRADA) with the National Cancer Institute (NCI), an Institute of the National Institutes of Health (NIH) to further develop therapeutic cancer vaccines.
Contract Research & Services > Contract Services > News
Valeant submits NDA to US FDA for oral Relistor to treat OIC in adults with chronic non-cancer pain
By PBR Staff Writer
Valeant Pharmaceuticals has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for Relistor (methylnaltrexone bromide) tablets designed to treat opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.
Contract Research & Services > Contract Services > News
BIND gets FDA authorization of first-in-human trial with AstraZeneca’s Accurin AZD2811
BIND Therapeutics (BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins, announced that the US Food and Drug Administration (FDA) has authorized the use of AstraZeneca’s Accurin AZD2811 in clinical trials under an investigational new drug (IND) application.
Contract Research & Services > Contract Services > News
Boehringer selects next generation of merchandising from Galleria
Leading pharmaceutical manufacturer, Boehringer Ingelheim have elected to improve the retail experience through the implementation of the next generation in micro space planning from Galleria.
Contract Research & Services > Contract Services > News
bioCSL secures worldwide rights to commercialize BioCryst' influenza treatment Rapivab
By PBR Staff Writer
BioCryst Pharmaceuticals has licensed worldwide rights to commercialize influenza treatment Rapivab (peramivir injection) to Australian biopharmaceutical firm CSL.
Contract Research & Services > Contract Services > News
View all Contract Services news or find news targeted to your interests